Dr. Matthias Eder of the German Cancer Research Center has been working on a new molecule that targets prostate-specific membrane antigen, a protein that clusters on the surface of prostate cancer cells.
Augmenix is trumpeting results from a study of its prostate cancer spacing device, promising data as the company charges ahead with development for the product after snagging FDA clearance in April.
New survey data show that 68% of men--nearly 7 in 10--sometimes ignore the symptoms of prostate cancer, putting off treatment for advanced forms of the disease. For Bayer--which markets cancer drug Xofigo to treat metastatic castration-resistant prostate cancer--that's far too many.
A group of investigators at Virginia Commonwealth University's Massey Cancer Center and the VCU Institute of Molecular Medicine say that a new animal study highlights the promise of a gene therapy tied to an experimental cancer drug in hitting metastatic prostate cancer.
In January, Germany's cost watchdog decided that Dendreon's--now Valeant's--Provenge had no added benefit for men with metastatic prostate cancer. But now, it's changing its tune.
GenomeDx Biosciences bagged Medicare coverage for its postoperative prostate cancer diagnostic, putting its test in the hands of more patients and helping the company gain ground in a crowded market.
Prostate cancer diagnostic research is taking interesting new steps toward personalized medicine in two separate projects, both involving The University of Texas MD Anderson Cancer Center.
Researchers from the U.K. and Italy have figured out two things that could improve both the diagnosis and ongoing treatment of advanced prostate cancer.
Just over a month after striking an immunotherapy pact with AstraZeneca, New Jersey biotech Advaxis is back with another Big Pharma agreement. This time, the company will be teaming up with Merck to test its cancer vaccine, ADXS-PSA, in combination with the latter's checkpoint inhibitor pembrolizumab.
The FDA's Gastroenterology & Urology Devices panel came down firmly against EDAP's Ablatherm system for treating low-risk, localized prostate cancer. The panel voted 9-0 on the device's effectiveness, 5-3 against its safety (with one abstention) and said the risks outweigh the benefits by a vote of 8-0 (with one abstention).